The UK Patent Box Regime: Reducing Corporation Tax on Intellectual Property Income

The UK Patent Box is an elective regime that reduces the effective rate of corporation tax on profits attributable to qualifying intellectual property to 10% — significantly below the standard corporation tax rate of 25% applicable since April 2023. For companies with IP-intensive businesses, the Patent Box can represent a material annual tax saving, improving cash generation, profitability, and competitiveness relative to jurisdictions with similar innovation regimes.

This guide explains how the regime works, what IP qualifies, how the qualifying profit is calculated, and how the Patent Box interacts with R&D tax credits and international tax planning.

Who Can Use the Patent Box?

The Patent Box is available to UK tax-resident companies and to UK permanent establishments of non-UK companies. The company must:

1. Own or exclusively licence qualifying intellectual property — patents granted by the UK Intellectual Property Office, the European Patent Office, or other specified European patent offices, as well as other similar rights (certain regulatory data exclusivity rights, supplementary protection certificates).
2. Have made a development contribution to the qualifying IP — either by itself or through a group member (the "nexus" requirement — explained below).
3. Actively elect into the Patent Box regime by filing an election in the company tax return (a company is not automatically included).

The election takes effect from the start of the accounting period in which it is made. Once elected, the company applies Patent Box treatment to all qualifying IP income unless it makes a formal revocation (subject to restrictions).

Qualifying Intellectual Property

Patents are the core qualifying IP. This includes:

• Patents granted by the UK Intellectual Property Office.
• Patents granted by the European Patent Office (EPO), including those with UK designation.
• Patents granted by specified EEA countries (Austria, Bulgaria, Czech Republic, Denmark, Estonia, Finland, Germany, Hungary, Poland, Portugal, Romania, Slovakia, Sweden).
• Supplementary protection certificates (SPCs) based on qualifying patents (common in pharmaceuticals).
• Plant variety rights (UK and EU).
• UK regulatory exclusivity rights (for pharmaceutical and biotechnology products).

What does NOT qualify: copyrights (including software copyrights, even if they embody inventions), trademarks, brand value, designs, and know-how that is not the subject of a patent. This is a common source of error — software companies sometimes assume their software copyright qualifies; it does not unless the underlying technology is separately patented.

A pending patent does not qualify the income immediately. However, there is a streaming-back mechanism: once a patent is granted, the company may elect to recover the Patent Box benefit retrospectively for the period since the patent application was filed (subject to a maximum look-back period of six years from the date the election is first made).

The Nexus Requirement

The nexus approach was introduced in 2016 to comply with OECD BEPS Action 5 (countering harmful tax practices). It ensures that Patent Box benefits are only available to the extent that the company (or its group) has genuinely performed the underlying R&D that created the IP.

The nexus fraction is calculated as:

D (qualifying expenditure) ÷ T (total expenditure)

Where:

• D = R&D expenditure incurred directly by the company (including expenditure subcontracted to unrelated third parties) on creating the qualifying IP.
• T = all R&D expenditure related to the qualifying IP, including expenditure by related party subcontractors (e.g., group company R&D) and expenditure on acquired IP.

This fraction is then multiplied by the qualifying IP profit to determine the amount eligible for the Patent Box rate. If the company performed all the relevant R&D itself, D equals T and 100% of the qualifying profit is within the Patent Box. If the company acquired the patent (without performing the underlying R&D), the nexus fraction may be significantly less than 1, limiting the benefit.

Practical implication: companies that purchase IP from group members or third parties receive reduced Patent Box benefit proportionate to their own R&D expenditure as a share of total expenditure on the IP. Companies that perform their own R&D maximise the nexus fraction and therefore the Patent Box benefit.

Qualifying IP Income

The Patent Box applies to "qualifying residual profit" derived from qualifying IP. Qualifying IP income includes:

• Royalties and licence fees from licensing the qualifying patent.
• Sales income from selling products that are protected by a qualifying patent. Where the product embodies multiple patents, all patent-protected products in the range are included.
• Infringement damages and compensation received in relation to qualifying IP.
• Income from the disposal of qualifying IP (where the IP itself is sold).

Importantly, not all income from a business that owns a patent is automatically qualifying IP income. The regime requires attribution of income to the specific patents. Companies must identify the products, processes, or services protected by each qualifying patent and attribute revenue accordingly.

The Calculation: Streaming vs Formulaic Methods

The Formulaic Method

For most companies, the qualifying Patent Box profit is calculated using a formulaic approach set out in the legislation (CTA 2010, Part 8A). The steps broadly involve:

1. Start with the company's total taxable profit.
2. Deduct a routine return — a return of 10% on "qualifying expenditure" (staff, premises, plant, etc.), representing the return a business would make without IP.
3. Deduct a marketing assets return — the proportion of profits attributable to brand value, marketing, and customer relationships rather than the patent itself.
4. The residual is the qualifying residual profit (QRP).
5. Multiply QRP by the nexus fraction (to reflect the company's own R&D contribution).
6. Apply the Patent Box rate (10%) to the result, rather than the standard 25% rate.

The Streaming Method

Where a company has clearly distinct income streams — for example, a pharmaceutical company with patent-protected products and unprotected generics — it may elect to use streaming: separating the income and expenditure of qualifying and non-qualifying activities and computing the Patent Box profit directly for the qualifying stream. This can be more favourable where qualifying activities are more profitable than the non-qualifying business.

Streaming is optional. Once elected, the company must use streaming consistently. Switching between streaming and formulaic methods requires HMRC agreement.

Interaction with R&D Tax Credits

R&D credits and the Patent Box are compatible and complementary: a company can claim both in respect of the same R&D activities and the resulting IP income. However, they operate at different stages of the value chain:

• R&D credits provide tax relief (or payable credits) when R&D expenditure is incurred.
• The Patent Box provides a reduced tax rate once the IP generates income.

The nexus fraction in the Patent Box calculation uses qualifying R&D expenditure as the numerator, so companies with strong R&D credit claims will typically have a high nexus fraction, maximising their Patent Box benefit. There is no legislative provision that reduces Patent Box benefit because R&D credits were also claimed.

For companies with large R&D credit claims that generate losses, the Patent Box may have limited immediate value (a loss-making company has no taxable profit on which the reduced 10% rate applies). In these cases, the Patent Box should be monitored for future periods when the company expects to be profitable.

International Considerations

Patent Box and Transfer Pricing

For international groups, the Patent Box raises transfer pricing questions. If the UK company licenses its patents to overseas affiliates (generating royalty income), the royalties must be at arm's length. HMRC will challenge both under-pricing (which reduces UK royalty income and therefore Patent Box benefit) and over-pricing (which may be considered transfer pricing manipulation).

Centralised IP structures: Groups that hold patents centrally (in a low-tax jurisdiction) and sub-license to operating companies will find the UK Patent Box available only where the UK is the patent owner or exclusive licensee — not where the UK pays royalties to an overseas IP holding company.

BEPS and Global Minimum Tax (Pillar Two)

Under the OECD's Pillar Two global minimum tax (the Global Anti-Base Erosion, or GloBE, rules), large multinationals (consolidated revenue above €750m) are subject to a minimum effective tax rate of 15%. The UK Patent Box's 10% rate is below this threshold, which may result in a top-up charge under Pillar Two for affected groups. The interaction between Patent Box and Pillar Two is complex; large multinational groups should model the combined effective rate before electing into the regime.

Worldwide Patent Royalties

Royalty income received from overseas licensees qualifies for the Patent Box, provided the UK company is the patent owner or exclusive licensee. This makes the UK Patent Box attractive for groups consolidating IP ownership in the UK — particularly given the UK's broad patent granting authority and established IP legal framework.

Practical Points for Companies Considering Patent Box

• File the patent application before income begins: the streaming-back benefit is limited; ideally the patent is in place before significant revenues arise from the protected product.
• Maintain nexus documentation: companies must keep records of qualifying R&D expenditure by IP category. Poor record-keeping means the nexus fraction cannot be substantiated on enquiry.
• Review regularly: as new patents are granted or existing ones expire, the qualifying IP income and the nexus fraction change. Annual review of the Patent Box position is essential.
• Consider the election timing: an election can be revoked, but once revoked the company cannot make a fresh Patent Box election for five years. Ensure the regime is beneficial before electing.

Compliance Caveat

The Patent Box regime is detailed legislation (CTA 2010, Part 8A) that has been amended multiple times since its introduction in 2013. The 10% rate, the nexus rules, the formulaic methodology, and the definition of qualifying IP are all subject to legislative change. The interaction with Pillar Two is an evolving area of international tax law. This guide reflects the law as at June 2026. Companies should obtain specialist IP tax advice before electing into the Patent Box and should review their election and nexus calculations annually. Incorrect Patent Box calculations can result in significant underpayment of corporation tax and penalties on enquiry.

How Global Investments Can Help

Global Investments works with businesses that own intellectual property to identify and maximise the value of tax incentives, including the Patent Box and R&D credits. For internationally mobile business owners and international groups, we advise on the structuring of IP ownership, transfer pricing, and the integration of UK tax incentives within the broader group tax strategy. Contact us to discuss your IP portfolio and whether the Patent Box represents a planning opportunity for your business.